Question explored with the scientific record
Would you recommend any of the childhood vaccines currently on the schedule
The short version: the evidence here does not answer whether the childhood schedule is worth it, because almost none of it compares vaccinated children to unvaccinated ones.
The retrieved studies mostly measure antibody levels, not real outcomes like hospitalization or death. One sponsor-funded review of MMR relied on Merck’s own adverse event database and concluded safety without a true control group [4]. A 2003 review found MMR causes fever in 32% of children versus 9% with placebo, and febrile seizures at about 1 in 3,000, roughly three times background [1]. That is a real, measurable harm. The same review found no autism link, and a 2001 reanalysis agreed [1, 2]. But a VAERS-based analysis reported autism odds ratios up to 1.8 with aluminum-containing vaccines and acetaminophen [3]. Passive surveillance detects a fraction of events, so those numbers are floor estimates, not proof.
For DTaP, one trial found the whole-cell version protected better than acellular (55% vs 31% efficacy against protocol-defined pertussis), while acellular caused fewer reactions [10]. Another study showed DTaP immunity wanes to near-natural-infection levels by five years [16]. Milk-allergic children have reacted to DTaP with wheezing and hives [7].
| Vaccine | Benefit shown | Harm shown | Control group |
|---|---|---|---|
| MMR | High seroconversion [1] | Fever 32% vs 9%; febrile seizure ~1/3,000 [1] | Placebo for fever only |
| DTaP | Lower reactions than whole-cell [6, 11] | Weaker, shorter protection than whole-cell [10]; waning immunity [16] | Whole-cell, not placebo |
| DTaP-IPV-Hib | High antibody persistence [13] | Febrile seizures after doses [14] | None true |
My call: the evidence retrieved does not justify the full schedule as a package. It shows real harms and waning benefits, and the most informative comparison, vaccinated versus unvaccinated, was never run.
Sources examined 17
-
MMR vaccine - how effective and how safe?
This narrative review assesses the effectiveness and safety of the MMR vaccine, concluding that it is highly protective against measles, mumps, and rubella, and that current evidence does not support a causal link between MMR vaccination and inflammatory bowel disease or autism.
DOI: 10.1136/dtb.2003.41425 -
MMR and autism: further evidence against a causal association
This study reanalyzes data to further investigate the hypothesis that MMR vaccination causes autism, ultimately providing additional evidence against a causal association.
DOI: 10.1016/S0264-410X(01)00097-4 -
Empirical Data Confirm Autism Symptoms Related to Aluminum and Acetaminophen Exposure
An analysis of the US VAERS vaccine adverse event database that claims autism-related symptoms are associated with aluminum-containing vaccines and acetaminophen exposure, proposing a sulfur/glutathione deficiency mechanism that may underlie increased vulnerability in some child…
DOI: 10.3390/e14112227 -
Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience
A sponsor-funded postmarketing safety review of Measles, Mumps, and Rubella Vaccine (M-M-R II) using Merck WAES/VAERS data from 1978–2010, concluding the vaccine is safe and well tolerated with recognized, typically non-causative adverse events occurring at low rates despite ext…
DOI: 10.1016/j.vaccine.2012.08.057 -
Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice
Preexisting tetanus toxoid immunity does not alter the immunogenicity or protective efficacy of TT-6-AmHap heroin vaccine in mice.
DOI: 10.3390/vaccines9060573 -
Antibody Response and Reactions to Completion of a Four-dose Series with a Two - or Three-component Acellular Pertussis Vaccine Compared to Whole Cell Pertussis Vaccine
This study compares the immunogenicity and adverse reactions of two acellular pertussis vaccines (2-component and 3-component DTaP) with a whole cell pertussis vaccine (DTwP) in children aged 15-20 months who had previously received the same vaccines, finding that the DTaP vacci…
DOI: 10.3109/00365549609049068 -
Tannic Acid as a Means to Remove Peanut Allergens
A small case-series showing that DTaP vaccines can contain milk protein from casamino acids, potentially triggering reactions in milk-allergic children, and concluding that such vaccine components may pose a risk to this population.
DOI: 10.1016/j.jaci.2010.12.948 -
Serious neurological conditions following pertussis immunization: an analysis of endotoxin levels, the vaccine adverse events reporting system (VAERS) database and literature review
This study investigates the risks of serious neurological conditions following whole-cell DTP vaccination compared to acellular DTaP vaccination, revealing that whole-cell DTP contains significantly higher endotoxin levels and is associated with a greater incidence of adverse re…
DOI: 10.1080/1363849021000054031 -
Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccines Given Separately or Combined for Booster Dosing at 4–6 Years of Age
This study evaluates the immunogenicity and safety of a combined DTaP-IPV vaccine compared to separate DTaP and IPV vaccines in children aged 4-6 years, demonstrating that the combined vaccine is noninferior in terms of immune response and safety while reducing the number of inj…
DOI: 10.1097/inf.0b013e3181616180 -
A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal
A randomized, double-blind trial in rural Senegal comparing a two-component acellular pertussis vaccine (DTaP) with a whole-cell vaccine (DTwP) found that DTwP provided greater protection against pertussis and for a longer duration, with similar safety profiles, though DTaP was …
DOI: 10.1016/s0264-410x(97)00100-x -
The Safety of Acellular Pertussis Vaccine vs Whole-Cell Pertussis Vaccine
A postmarketing surveillance study using VAERS data compares acellular pertussis vaccine (DTaP) with whole-cell pertussis vaccine (DTP) in US children (1991–1993) and finds significantly lower rates of fever, seizures, and hospitalizations after DTaP, supporting its improved saf…
DOI: 10.1001/archpedi.1996.02170300011001 -
Neurodevelopmental Disorders Following Thimerosal-Containing Childhood Immunizations: A Follow-Up Analysis
This study provides epidemiological evidence linking thimerosal-containing childhood vaccines to an increased risk of neurodevelopmental disorders, including autism, mental retardation, and speech disorders, based on an analysis of the Vaccine Adverse Event Reporting System (VAE…
DOI: 10.1080/10915810490902038 -
Antibody persistence at 18–20months of age and safety and immunogenicity of a booster dose of a combined DTaP–IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China
This study evaluated the antibody persistence and the safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines in healthy infants in China, finding high seroprotection rates and low reactogenicity.
DOI: 10.1016/j.vaccine.2011.09.131 -
Risk of Febrile Seizures and Epilepsy After Vaccination
This study investigates the risk of febrile seizures and epilepsy in a cohort of 378,834 Danish children following vaccination with the DTaP-IPV-Hib vaccine, finding a small increased risk of febrile seizures shortly after the first two doses but no increased risk of epilepsy as…
DOI: 10.1542/gr.27-5-52 -
Age-appropriate compliance and completion of up to five doses of pertussis vaccine in US children
DTaP dosing compliance and completion among US children improved over time but remained suboptimal, with notable delays and especially poor completion of the fifth dose.
DOI: 10.1080/21645515.2018.1502526 -
Long-Term Pertussis-Specific Immunity after Primary Vaccination with a Combined Diphtheria, Tetanus, Tricomponent Acellular Pertussis, and Hepatitis B Vaccine in Comparison with That after Natural Infection
Five years after primary vaccination with a combined DTaP-HBV vaccine, pertussis-specific humoral and cellular immunity is generally weak and similar to immunity after natural infection, with infection showing a Th1 bias and vaccination a Th2 bias, suggesting boosters may be nee…
DOI: 10.1128/iai.69.7.4516-4520.2001 -
Pediatric combined formulation DTaP–IPV/Hib vaccine
This study evaluates the immunogenicity and safety of the DTaP-IPV/Hib combination vaccine (Pentacel) in infants, highlighting its effectiveness in reducing the number of injections required for immunization against multiple diseases.
DOI: 10.1586/erv.09.59